Menu

Image of the Day: Tadpole Prism

Scientists are making use of Xenopus tadpoles to study autism risk genes. 

Nov 3, 2017
The Scientist Staff, The Scientist Staff

A confocal tiled image of a Xenopus laevis tadpole, showing the neural tract and brain (green), muscle (red), and cell nuclei (blue). HELEN WILLSEY, UNIVERSITY OF CALIFORNIA, SAN FRANCISCOScientists are using tadpoles to study the roles of genes associated with autism spectrum disorder during neurodevelopment. In this Xenopus laevis youngster, the neural system and brain has been stained green (using beta tubulin as a neuronal marker), the muscle stained red (using phalloidin), and cell nuclei stained blue (using DAPI, a blue-fluorescent DNA stain). 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.